Cell Line Development Market Set to Register 13.0% CAGR During 2018-2024 | Top Companies – GE Healthcare, Thermo Fisher Scientific, Lonza Group, Cytovance Biologics, Sartorius, Corning, Selexis, Vista Biologicals, EuBiologics, Paragon Bioservices

Market Study Report recently introduced new title on “2018-2024 Global Cell Line Development Market Report” that provides an in-depth overview of industry and competitive landscape, covering multiple market segments and elaborates market outlook and status to 2024.

U.S. cell line development market valued around USD 1.1 billion in 2017 and estimated to grow considerably during the forecast timeframe. Launch of sophisticated cell line development technologies, well-established healthcare infrastructure and large-scale production of protein therapeutics will drive the U.S. cell line development market during the forecast timeframe.

Increasing incidences of cancer coupled with growing demand for monoclonal antibodies and vaccines will drive cell line development market. Rising prevalence of cancer has become major healthcare concern globally, hence government and several other organizations are conducting extensive research to reduce disease burden one of such approach includes cancer cell line development. Cell Line Development Market will reach over USD 7.5 billion by 2024; as per a new research report.

Request a sample of this premium report at: https://www.marketstudyreport.com/request-a-sample/467705/

High alcohol and tobacco consumption coupled with unhealthy food and physical inactivity will escalate number of cancer incidences. Growth of biotechnology sector will positively impact cell line development market growth. Biotechnology based applications of cell line industry includes cell culture, drug discovery and gene therapy will grow significantly in coming future.

Patent expiration of blockbuster biologics such as Neupogen leading to development of new biosimilars should increase demand for human and animal cell lines. Thereby, accelerating industry expansion. Technological advancements in cell line development including automated screening methods, disposable equipment, enriched medias, improved expression systems and monitoring processes will drive industry growth. However, stringent regulations along with various concerns associated with stem cell research will hamper industry growth over the coming years.

Reagents and media product segment dominated the industry in 2017 owing to high usage of reagents and media in tissue engineering, toxicity testing, research, bioproduction, development of regenerative medicine and others. It forms essential component for cell line development and cell culture procedures will drive industry growth. Non-mammalian source segment is estimated to grow considerably during the forecast period owing to high application in insecticide screening and toxicology study.

Request a discount on standard prices of this premium report at: https://www.marketstudyreport.com/check-for-discount/467705/

Based on application type, the industry is bifurcated into bioproduction, toxicity testing, drug discovery, tissue engineering and research. Tissue engineering segment will witness robust growth rate during the forecast period due to increasing investment in R&D coupled with rising demand for advanced cancer treatment.

High incident rate of cancer, favorable reimbursement for biologics and rising demand for monoclonal antibodies, vaccines and gene therapy will drive France cell line development market over the coming years. Presence of associations such as The French National Cancer Institute (INCa) working towards reducing cancer prevalence will positively impact the industry growth.

Few notable industry players operating in cell line development market are GE Healthcare, Thermo Fisher Scientific, Lonza Group, Sigma-Aldrich Corporation (Merck), Cytovance Biologics, WuXi AppTec, Sartorius, Corning, Selexis, Vista Biologicals, EuBiologics, Paragon Bioservices, Cobra Biologics, Patheon, Samsung Biologics, NAEJA RGM Pharmaceuticals, GVK BIO, Catalent and others. Industry players are focusing towards expanding business portfolio to consolidate their market position as well as increase consumer base. For instance, In February 2017, Lonza entered into strategic partnership with Sanofi, that aimed at building mammalian cell facilities to produce monoclonal antibodies in Switzerland.

Table of Content:

Chapter 1. Methodology

1.1. Methodology

1.2. Market definitions

1.3. Forecast parameters

1.4. Data Sources

1.4.1. Secondary

1.4.1.1. Paid Sources

1.4.1.2. Unpaid Sources

1.4.2. Primary

Chapter 2. Executive Summary

2.1. Cell line development industry 360 degree synopsis, 2013 - 2024

2.1.1. Business trends

2.1.2. Product trends

2.1.3. Source trends

2.1.4. Cell line type trends

2.1.5. Application trends

2.1.6. Regional trends

Chapter 3. Cell Line Development Industry Insights

3.1. Industry segmentation

3.2. Industry landscape, 2013 - 2024

3.3. Industry impact forces

3.3.1. Growth drivers

3.3.1.1. Rise in production of vaccines globally

3.3.1.2. Increasing number of cancer incidences especially in developing countries such as India and China

3.3.1.3. Extended applications of biotechnology sector

3.3.1.4. Patent expiration of blockbuster biologics leading to innovations in the field

3.3.1.5. Escalating demand for monoclonal antibodies in U.S. and Europe

3.3.1.6. Technological advancements in cell line development

3.3.2. Industry pitfalls & challenges

3.3.2.1. Ambiguous regulatory landscape

3.3.2.2. Growing concerns related to stem cell research

3.4. Growth potential analysis

3.4.1. By product

3.4.2. By source

3.4.3. By cell line type

3.4.4. By application

3.5. Porter's analysis

3.6. Regulatory landscape

For more information on this report, Please visit at: https://www.marketstudyreport.com/reports/cell-line-development-market/?utm_source=OPR-SP

Related Report:

2018-2023 Global Cell Line Development Market Report (Status and Outlook)

The process of developing stable cell lines often starts with transfecting selected host cells, typically CHO or HEK 293 cells with desired plasmids. There is an increase in demand for the cell line development market owing to the increasing demand for monoclonal antibodies, rising vaccine production and use of innovative technologie.

https://www.marketstudyreport.com/reports/2018-2023-global-cell-line-development-market-report-status-and-outlook?utm_source=RR-SP

About Us:
Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

Contact Us:
Market Study Report
4 North Main Street,
Selbyville, Delaware 19975
USA
Phone: 1-302-273-0910
US Toll Free: 1-866-764-2150
Email:sales@marketstudyreport.com
Website:https://www.marketstudyreport.com
Blog: https://www.marketstudyreport.com/blog/

This release was published on openPR.